MECP2 Antisense Composition for Reducing Expression Without Rett-Like Symptoms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders associated with MECP2 overexpression, such as MECP2 duplication syndrome, are lacking in effectiveness and safety.
Innovation Solution
The use of modified antisense oligonucleotides that specifically target MECP2 mRNA and protein, reducing their expression levels in animals, including humans, to treat, prevent, or ameliorate associated neurological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MECP2 expression is reduced to treat MECP2 duplication syndrome, then neurological symptoms are ameliorated, but MECP2 expression may be reduced too much causing Rett Syndrome-like symptoms
Solution Approach 1:
The patent employs modified antisense oligonucleotides with specific chemical modifications (2'-O-methoxyethyl, phosphorothioate linkages, bicyclic sugars) to precisely control the degree of MECP2 expression reduction. These parameter changes in the oligonucleotide structure enable selective binding and degradation of MECP2 mRNA while maintaining expression within a safe therapeutic range that avoids Rett Syndrome-like symptoms.
Solution Approach 2:
The antisense oligonucleotides act as intermediary molecules that mediate between the therapeutic goal (reducing MECP2) and the safety constraint (avoiding Rett Syndrome). By designing oligonucleotides with specific sequences complementary to MECP2 mRNA and incorporating stabilizing modifications, they selectively reduce MECP2 expression without affecting other critical biological processes.
2Quantity of substance
If antisense compounds are used to reduce MECP2 mRNA levels, then MECP2 protein expression is reduced, but off-target effects and toxicity may occur
Solution Approach 1:
The patent applies local quality by incorporating specific chemical modifications at different positions of the oligonucleotide sequence. The 2'-O-methoxyethyl modifications at terminal positions enhance stability and reduce immunogenicity, while phosphorothioate linkages at specific positions improve nuclease resistance. These localized modifications allow the compound to achieve high MECP2 mRNA reduction while minimizing off-target effects and toxicity.
Solution Approach 2:
The antisense oligonucleotides are composite molecules combining multiple modified nucleoside types (2'-O-methoxyethyl, phosphorothioate, bicyclic sugars) in a single sequence. This composite structure integrates the benefits of each modification type: enhanced stability, improved cellular uptake, increased binding affinity, and reduced immunogenicity, thereby achieving effective MECP2 suppression with minimal toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The administration of MECP2 antisense compounds effectively reduces MECP2 mRNA and protein levels, thereby improving symptoms and slowing the progression of MECP2 duplication syndrome without causing Rett Syndrome-like symptoms.
Implementation Method 1
antisense compounds are single-stranded antisense oligonucleotides
Data Source
AI summary
Disclosed herein are compounds and methods for decreasing MECP2 mRNA and protein expression. Such compounds and methods are useful to treat, prevent, or ameliorate MECP2 associated disorders and syndromes. Such MECP2 associated disorders include MECP2 duplication syndrome.